Clinical Trials Logo

Refractory Hematologic Cancer clinical trials

View clinical trials related to Refractory Hematologic Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03882203 Completed - Clinical trials for Allogeneic Stem Cell Transplantation

CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

For patients with refractory acute leukemia, allogeneic stem cell transplantation is the only curative therapy. Only 20% of patients may achieve long-term survival mostly due to relapse or nor-relapse mortality (NRM). In previous study, we demonstrated that intensive leukemia debulking chemotherapy FLAG-IDA sequential with Flu-BU conditioning is feasible with ~40% long-term survival. In the study, we further modified the chemotherapy with cladribine replacing fludarabine aiming a more potent anti-leukemia effect. Meanwhile, we reduce the dose of busulfan for patients with poor performance status and age over 45 aim to reduce the NRM. All patients will also receive post-transplantation maintenance therapy with low-dose decitabine to prevent relapse.